可能患有MSA的印度人的快速进展和更短的存活时间:前性队列研究
Malligurki Raghurama Rukmani1, Ravi Yadav2, Binukumar Bhaskarapillai3
1Department of Neurophysiology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.
Movement disorders clinical practice
|August 25, 2025
概括
多重系统缩 (MSA) 患者表现出快速进展和自主性衰竭,在亚洲-印度群体中存活时间较短. 血清α-synuclein的升高与疾病的严重程度相关,表明其作为生物标志物的潜力.
科学领域:
- 神经退行性疾病
- 阿尔法同核病变
- 多个系统缩 (MSA)
背景情况:
- 多重系统缩 (MSA) 是一种致命的神经退行性疾病,其特征是帕金森症,自主功能障碍和小脑症状.
- 了解MSA的自然史和进展对于患者的治疗和治疗发展至关重要.
研究的目的:
- 对可能的MSA自然史进行前性调查,重点关注心血管自主功能障碍 (CAD) 和血清α-synuclein水平.
- 评估可能的MSA患者的疾病进展,生存概率和预后因素.
主要方法:
- 招募了60名可能的MSA患者 (MSA- P:19,MSA- C:41) 和30名健康对照.
- 通过ELISA在基线和12个月的随访评估疾病的严重程度 (UPDRS III,UMSARS I- IV),CAD和血清α-synuclein.
- 使用卡普兰-梅尔和考克斯的比例危险分析来评估生存和预后因素.
主要成果:
- 开始时MSA患者的血清α-synuclein和严重的CAD水平较高,在12个月后情况进一步恶化.
- 心血管自主功能障碍 (CAD) 与血清α-synuclein和疾病严重程度正相关.
- 在MSA- C患者中,疾病的进展比MSA- P患者更快,该队列的中位生存时间为5. 8年.
结论:
- 这一亚洲-印度队列中可能的MSA患者经历了快速进展和自主性衰竭,与全球队列相比,其存活时间更短.
- 与CAD和疾病严重程度相关的血清α-synuclein升高显示为MSA的潜在生物标志物.
- 与MSA-C患者相比,MSA-P患者的预后更好.
相关概念视频
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
01:24Kaplan-Meier Approach
260
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
260
01:15Assumptions of Survival Analysis
196
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
196
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
01:20Comparing the Survival Analysis of Two or More Groups
285
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
285